Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children
Primary Purpose
Influenza Virus Infection
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Inactivated influenza vaccine
Saline
Sponsored by
About this trial
This is an interventional prevention trial for Influenza Virus Infection focused on measuring influenza, vaccination, children, Influenza-like illness
Eligibility Criteria
Inclusion Criteria:
- All vaccinees must be Hong Kong residents aged between 6 and 17.
Exclusion Criteria:
- Vaccinees should not be allergic or hypersensitive to the active substances or components (eggs, chicken proteins, formaldehyde, neomycin, etc.) used in the vaccines or where vaccination is otherwise contraindicated. Subjects should not have an underlying immunocompromised condition or be receiving immunosuppressive agents.
Sites / Locations
- The University of Hong Kong
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
Influenza vaccine
Outcomes
Primary Outcome Measures
The proportions of subjects and household contacts with serology-confirmed influenza infection during follow-up among the 2 intervention arms.
Secondary Outcome Measures
Full Information
NCT ID
NCT00792051
First Posted
November 13, 2008
Last Updated
December 29, 2014
Sponsor
The University of Hong Kong
Collaborators
Research Fund for the Control of Infectious Diseases, Research Grants Council, Hong Kong, Centre for Health Protection, Hong Kong
1. Study Identification
Unique Protocol Identification Number
NCT00792051
Brief Title
Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children
Official Title
A Randomised Controlled Trial of the Effectiveness of Vaccinating Children to Reduce Household Transmission of Influenza
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
The University of Hong Kong
Collaborators
Research Fund for the Control of Infectious Diseases, Research Grants Council, Hong Kong, Centre for Health Protection, Hong Kong
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
While immunisation of school-age children against influenza is not recommended in Hong Kong, past experience in Japan and elsewhere suggests that immunisation of children may protect the wider community through its indirect transmission-limiting impact as well as the direct immunologic protection afforded vaccinated children themselves. We aim to assess whether vaccinating children against influenza protects vaccinees as well as their household contacts from infection.
Detailed Description
Design and subjects: A double-blind randomised controlled trial of 800 subjects aged 6-17 drawn from the general population and their 2000 household contacts. The subjects will be randomised in a 3:2 ratio to the intervention and placebo groups, respectively. Serum samples will be collected from subjects pre- and 1 month post-vaccination, and after the influenza season. Serum samples will be collected from household contacts at baseline and at the end of the influenza season. During the follow-up period, subjects and household members will keep symptom diaries and those reporting influenza-like-illness will be offered free doctor consultations or home visits where we will arrange for collection of nose and throat swabs.
Study instruments: An antibody titre of ≥40 in the post-vaccine serum will be used to define seroprotection to those particular strains, while a four-fold or higher increase in antibody titres between baseline and end-of-season follow-up of the household contacts will define influenza infection during the season. Subjects and household contacts will be asked to keep symptom diaries, and during episodes of ILI we will collect nose and throat swabs for laboratory confirmation of influenza infection; the primary serology results will then be compared with clinical and laboratory-confirmed influenza episodes.
Interventions: 1 (intervention) inactivated influenza vaccine (Vaxigrip, Sanofi Pasteur); 2 (placebo) saline injection.
Main outcome measures: The proportions of subjects and household contacts with serology-confirmed influenza infection during follow-up among the 2 intervention arms.
Analysis: Intention to treat, adjusting for within-household correlation in influenza attack rates.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza Virus Infection
Keywords
influenza, vaccination, children, Influenza-like illness
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
2800 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Influenza vaccine
Arm Title
2
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
Inactivated influenza vaccine
Other Intervention Name(s)
VAXIGRIP®, Sanofi Pasteur
Intervention Description
0.5ml intramuscular single dose
Intervention Type
Biological
Intervention Name(s)
Saline
Intervention Description
0.5ml intramuscular, one dose
Primary Outcome Measure Information:
Title
The proportions of subjects and household contacts with serology-confirmed influenza infection during follow-up among the 2 intervention arms.
Time Frame
nine months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
All vaccinees must be Hong Kong residents aged between 6 and 17.
Exclusion Criteria:
Vaccinees should not be allergic or hypersensitive to the active substances or components (eggs, chicken proteins, formaldehyde, neomycin, etc.) used in the vaccines or where vaccination is otherwise contraindicated. Subjects should not have an underlying immunocompromised condition or be receiving immunosuppressive agents.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin J Cowling, PhD
Organizational Affiliation
The University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Hong Kong
City
Hong Kong
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
22670050
Citation
Cowling BJ, Ng S, Ma ES, Fang VJ, So HC, Wai W, Cheng CK, Wong JY, Chan KH, Ip DK, Chiu SS, Peiris JS, Leung GM. Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clin Infect Dis. 2012 Sep;55(5):695-702. doi: 10.1093/cid/cis518. Epub 2012 Jun 5.
Results Reference
result
PubMed Identifier
21067351
Citation
Cowling BJ, Ng S, Ma ES, Cheng CK, Wai W, Fang VJ, Chan KH, Ip DK, Chiu SS, Peiris JS, Leung GM. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis. 2010 Dec 15;51(12):1370-9. doi: 10.1086/657311. Epub 2010 Nov 10.
Results Reference
result
PubMed Identifier
24825868
Citation
Cowling BJ, Perera RA, Fang VJ, Chan KH, Wai W, So HC, Chu DK, Wong JY, Shiu EY, Ng S, Ip DK, Peiris JS, Leung GM. Incidence of influenza virus infections in children in Hong Kong in a 3-year randomized placebo-controlled vaccine study, 2009-2012. Clin Infect Dis. 2014 Aug 15;59(4):517-24. doi: 10.1093/cid/ciu356. Epub 2014 May 13.
Results Reference
derived
Learn more about this trial
Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children
We'll reach out to this number within 24 hrs